Compare TG Therapeutics Inc (TGTX) vs Financial Select Sector SPDR Fund (XLF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Financial Select Sector SPDR Fund — how do they compare? TG Therapeutics Inc trades at $54 (market cap $8.26B), while Financial Select Sector SPDR Fund trades at $56.1. Which is the better fit depends on your goals.
| TGTX | XLF | |
|---|---|---|
Market Cap | $8.26B | — |
Sector | Health | — |
52-Week High | $59.06 | $56.75 |
52-Week Low | $26.39 | $47.80 |
Enterprise Value | $8.50B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $53.96, down 1.6% today, with a bullish technical signal and strong profitability metrics including a 65.95% net income margin. Recent news highlights clinical progress, including a Phase 2 trial for Briumvi in schizophrenia (Zacks Investment Research, 2026-07-07) and positive Phase 1 data for subcutaneous Briumvi (GlobeNewsWire, 2026-06-03). However, earnings misses in Q4 2025 and Q1 2026 and a shareholder investigation (PRNewsWire, 2026-07-21) introduce volatility.
The outlook is mixed: analyst consensus is strongly bullish (84.6% buy ratings) with a $48.50 price target, but near-term risks from legal scrutiny and earnings inconsistency warrant caution. Upside hinges on successful drug trials and sales growth, while downside risks include legal outcomes and competitive pressures in the biotech sector.
XLF trades at $56.04, down 0.39% today, with technical indicators showing a bullish trend supported by moving averages while oscillators remain neutral. The ETF holds 76 financial companies and benefits from strong bank earnings, with recent news highlighting its low expense ratio of 0.08% and exposure to diversified financials. Geopolitical tensions and potential Federal Reserve rate hikes are key market drivers.
Outlook remains positive due to robust sector earnings and potential rate hike benefits, though risks include geopolitical volatility and high investor expectations. Wall Street sentiment is cautiously optimistic, with technical support near $56.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Financial Select Sector SPDR Fund
The fund generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: diversified financial services; insurance; banks; capital markets; mortgage real estate investment trusts; consumer finance; thrifts; and mortgage finance. The fund is non-diversified.
Read more on XLF →
